Spectral AI (MDAI) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Spectral AI (MDAI) right now is FDA clearance opens the U.S. market: In May 2026 Spectral AI received FDA De Novo clearance for the DeepView System's burn indication, the regulatory milestone the company had worked toward for years. Revenue (FY2025, mostly research/BARDA) is ~$19.7 million R&D revenue, down from ~$29.6 million in 2024. If that keeps playing out, the setup is favourable; the risk to it is the risks are substantial and concentrated. No one can predict where MDAI trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Spectral AI (MDAI) higher?
1. FDA clearance opens the U.S. market.
In May 2026 Spectral AI received FDA De Novo clearance for the DeepView System's burn indication, the regulatory milestone the company had worked toward for years. Clearance authorizes commercial distribution in the United States and is the gate to any meaningful product revenue. Management has signaled it hopes to begin commercializing DeepView by the end of 2026 and is working with Deloitte Consulting on its go-to-market strategy. The opportunity now shifts from getting approved to actually selling and getting reimbursed.
2. Non-dilutive government funding.
Spectral AI's development has been financed largely by government contracts, with roughly $282.5 million awarded since 2013, the bulk from BARDA. The company highlighted $31.7 million in advanced, non-dilutive BARDA funding tied to an accelerated phase of its Project BioShield contract, plus DoD support for a handheld module. This funding has let it build the technology with far less shareholder dilution than a typical pre-revenue device company, though it also means most reported revenue is reimbursed research cost, not commercial sales.
3. Large clinical and addressable need.
Assessing burn depth and wound healing is notoriously subjective, and accurate early triage can change whether a patient needs surgery. DeepView aims to standardize that judgment with an objective AI read at the bedside. Beyond initial burn use in burn, trauma, and emergency settings, the company has discussed extending the platform to chronic wounds such as diabetic foot ulcers, a far larger long-term market if the technology proves out and earns its own clearances.
4. Commercial build-out underway.
With clearance in hand, Spectral AI is assembling commercial infrastructure: it has been searching for a chief commercial officer, engaged outside consultants on launch strategy, and continued developing a more portable Snapshot module funded by the DoD. Whether these steps convert into installed systems, recurring usage, and reimbursement is the central unknown. Management has guided that 2026 revenue stays roughly flat at about $18.5 million, mostly BARDA-funded, with 2027 and 2028 framed as the intended growth years.
What could weigh on MDAI?
The risks are substantial and concentrated. Even with De Novo clearance, commercialization risk is high: Spectral AI has almost no track record of selling product, and revenue, hospital adoption, and reimbursement for a novel AI imaging device are all unproven. The company depends heavily on government funding, so changes to BARDA or DoD contracts could sharply reduce the revenue it reports today. It is unprofitable and burns cash, with only about $11.7 million on hand at March 31, 2026 against ongoing losses, which makes further dilution through equity, warrants (MDAIW), or debt likely. As a micro-cap with roughly 31.8 million shares and a market value frequently in the tens of millions, the stock is thinly traded and highly volatile, and it faces competition from other wound-imaging and AI-diagnostics approaches as well as the inertia of standard visual assessment.
How to think about a MDAI forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the MDAI guide and whether MDAI is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the MDAI outlook
The bottom line: what is driving Spectral AI (MDAI) is FDA clearance opens the U.S. market, with revenue (fy2025, mostly research/barda) at ~$19.7 million R&D revenue, down from ~$29.6 million in 2024. If that keeps playing out the setup is favourable; the risk is the risks are substantial and concentrated. No one can predict the price, so treat any MDAI forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around MDAI with Walnut
Use Spectral AI as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Spectral AI (MDAI)?
+
No one can reliably predict where MDAI will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Spectral AI higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive MDAI higher?
+
The main growth drivers are FDA clearance opens the U.S. market; Non-dilutive government funding; Large clinical and addressable need. Whether they play out is the real question, not a guaranteed path.
What are the risks to MDAI?
+
The risks are substantial and concentrated. Even with De Novo clearance, commercialization risk is high: Spectral AI has almost no track record of selling product, and revenue, hospital adoption, and reimbursement for a novel AI imaging device are all unproven. The company depends heavily on government funding, so changes to BARDA or DoD contracts could sharply reduce the revenue it reports today. It is unprofitable and burns cash, with only about $11.7 million on hand at March 31, 2026 against ongoing losses, which makes further dilution through equity, warrants (MDAIW), or debt likely. As a micro-cap with roughly 31.8 million shares and a market value frequently in the tens of millions, the stock is thinly traded and highly volatile, and it faces competition from other wound-imaging and AI-diagnostics approaches as well as the inertia of standard visual assessment.
Will MDAI stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Spectral AI's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is MDAI a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the MDAI "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.